Hide metadata

Economic evaluation of Pembrolizumab combination therapy compared to standard of care chemotherapy as a first-line treatment for previously untreated, metastatic, non-squamous patients with metastatic non-small cell lung cancer (NSCLC)

dc.contributor.authorKantorova, Dominika
dc.date.accessioned2020-11-06T23:48:47Z
dc.date.available2020-11-06T23:48:47Z
dc.date.issued2020
dc.identifier.citationKantorova, Dominika. Economic evaluation of Pembrolizumab combination therapy compared to standard of care chemotherapy as a first-line treatment for previously untreated, metastatic, non-squamous patients with metastatic non-small cell lung cancer (NSCLC). Master thesis, University of Oslo, 2020
dc.identifier.urihttp://hdl.handle.net/10852/80931
dc.description.abstracteng
dc.language.isoeng
dc.subject
dc.titleEconomic evaluation of Pembrolizumab combination therapy compared to standard of care chemotherapy as a first-line treatment for previously untreated, metastatic, non-squamous patients with metastatic non-small cell lung cancer (NSCLC)eng
dc.typeMaster thesis
dc.date.updated2020-11-07T23:45:51Z
dc.creator.authorKantorova, Dominika
dc.identifier.urnURN:NBN:no-84013
dc.type.documentMasteroppgave
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/80931/1/Economic-evaluation-of-Pembrolizumab-combination-therapy-compared-to-standard-of-care-chemotherapy-as-a-first-line-treatment-for-previously-untreated--metastatic--non-squamous-patients-with-metastatic-non-small-cell-lung-cancer--NSCLC-.pdf


Files in this item

Name:
Economic-evaluation-of-Pembrol ...
Size:
2.436Mb
Format:
application/
View/Open

Appears in the following Collection

Hide metadata